LeMaitre Vascular, Inc. is a global provider of medical devices and human tissue cryopreservation services used primarily in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices for vascular surgeons, cardiac surgeons, general surgeons, and neurosurgeons, with a portfolio spanning biologic grafts, synthetic grafts, valve cutters, shunts, and cryopreserved allografts. Key products include the LeMaitre Valvulotome, XenoSure patches, Artegraft biologic grafts, RestoreFlow cryopreservation services, and various shunt and catheter systems. The company sells its products primarily through a direct sales force in North America, Europe, and Asia Pacific, with additional distribution in other regions. Founded in 1983 by George D. LeMaitre, M.D., the company has expanded its portfolio through numerous acquisitions, including VascuTape, TufTex, Endomed, and RestoreFlow. LeMaitre Vascular serves hospitals and surgical centers worldwide, focusing on open vascular surgeries and dialysis access procedures.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage lemaitre.com
Sector Healthcare IR page ir.lemaitre.com
Tags
vascular surgery, peripheral vascular disease, biologic grafts, tissue cryopreservation, valve cutters, shunts, dialysis access, open surgery, endovascular procedures, cardiovascular disease, LeMaitre Valvulotome, XenoSure, CardioCel, VascuCel, Artegraft, RestoreFlow, Omniflow II, VascuTape, TufTex, Pruitt F3 Shunt, Credent, AnastoClip, Endomed, LeverEdge, MollRing Cutter, UnBalloon, AlboGraft, LifeSpan, Pruitt F3-S Shunt, TRIVEX, PeriVu, Eze-Sit OUS, ProCol, Syntel, Cardial, Eze-Sit US, AndraValvulotome
Press page —

Metrics

Valuation  
Market cap $ 1.89B
Market cap (USD) $ 1.89B
P/E 29.92
PEG 0.73
P/BV 4.37
P/S 7.02
P/OCF 24.80
P/FCF 28.20
Dividend yield 1.2%
Turnover / mcap —
Returns  
ROE 15.8%
ROI 10.3%
ROIC 9.3%
Profit margin 23.1%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 40.9%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 42.9%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 15
Quality score 42.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005
Revenue 249.602M 219.863M 193.484M 161.651M 154.424M 129.366M 117.232M 105.568M 100.867M 89.151M 78.352M 71.097M 64.549M 56.735M 57.685M 56.06M 50.908M 48.72M 41.446M 34.628M 30.727M
Net profit 57.734M 44.038M 30.105M 20.636M 26.907M 21.22M 17.934M 22.943M 17.177M 10.59M 7.758M 3.915M 3.202M 2.571M 2.143M 6.013M 1.598M -3.314M -2.934M -1.172M 55K
Free cash flow 74.468M 37.162M 29.486M 22.149M 30.22M 31.818M 10.418M 16.452M 16.451M 14.055M 9.165M 4.338M 2.655M 3.513M 1.149M 4.581M 4.863M -43K -2.946M -1.495M -2.215M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005
Share price 81.1 92.14 56.76 46.02 50.23 40.5 35.95 23.64 31.84 25.34 17.25 7.65 8.01 6.41 5.47 7.2 5 3.16 6 6.05 —
Price performance 12m -0.12 0.62 0.23 -0.08 0.24 0.13 0.52 -0.26 0.26 0.47 1.26 -0.04 0.25 0.17 -0.24 0.44 0.58 -0.47 -0.01 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 13.2M 15M 15.7M 16.6M 19.6M 19.6M 22M 25.1M 30.1M 33.6M
↳ YoY growth +10.2% +13.7% +4.8% +5.4% +18.0% +0.4% +12.3% +13.7% +19.9% +11.8%
↳ 5y CAGR +9.1% +10.6% +8.2% +8.9% +10.3% +8.3% +8.0% +9.8% +12.7% +11.4%
Lease liabilities (USD) — — — 15.7M 16.7M 15.9M 16.6M 19.1M 17.9M 16.9M
Cash and deposits (USD) 24.3M 19.1M 26.3M 11.8M 26.8M 13.9M 19.1M 24.3M 25.6M 28.2M
Intangible assets (USD) 9.9M 8.23M 13.7M 24.9M 58.9M 52.7M 46.5M 41.7M 35.8M 33.1M
Right-of-use assets (USD) — — — 15.2M 16.1M 15.1M 15.6M 18M 16.8M 15.8M
Cash flow detail
Operating cash flow (USD) 16.9M 22.9M 19.5M 14.2M 34.8M 35.1M 25.4M 36.8M 44.1M 81.3M
Purchases of property, plant and equipment (USD) -2.84M -6.42M -3.05M -3.76M -2.98M -4.88M -3.23M -7.27M -6.96M -6.78M
Purchases of intangible assets (USD) -2,000 — — — — — — — — —
Change in receivables (cash effect) (USD) -922,000 -1.51M -1.28M -1.3M -939,000 -818,000 -3.53M -3.14M -6.42M -2.95M
Dividends paid (cash effect) (USD) -3.32M -4.18M -5.45M -6.74M -7.7M -9.34M -11M -12.4M -14.4M -18.1M
Share buybacks (cash effect) (USD) -311,000 -778,000 -741,000 -683,000 -570,000 -802,000 -642,000 -853,000 -1.72M -1.82M
Income taxes paid (cash effect) (USD) -4.23M -3.15M -5.52M -4.82M -4.47M -10.1M -8.34M -7.55M -12.8M -13.4M
Share-based compensation (USD) 1.68M 2.26M 2.35M 2.64M 3.02M 3.48M 4.17M 5.32M 6.57M 7.83M
Operating cash flow before change in receivables (USD) 17.8M 24.4M 20.8M 15.5M 35.7M 35.9M 28.9M 39.9M 50.5M 84.2M
Free cash flow (OCF - PPE - intangibles) (USD) 14.1M 16.5M 16.5M 10.4M 31.8M 30.2M 22.1M 29.5M 37.2M 74.5M
Income detail
Research and development expense (USD) 6.14M 6.64M 8.2M 9.28M 10.1M 11.8M 13.3M 17M 15.7M 14.1M
↳ 5y CAGR +6.8% +5.4% +9.3% +14.7% +13.0% +14.0% +14.9% +15.7% +11.0% +7.0%
Total comprehensive income (USD) 10.1M 19.5M 21.3M 17.8M 23.7M 25M 18M 31.5M 42.5M 61.5M
Comprehensive income to owners (USD) 10.1M 19.5M 21.3M 17.8M 23.7M 25M 18M 31.5M 42.5M 61.5M
Provision for credit losses (USD) 105,000 230,000 264,000 388,000 293,000 263,000 637,000 344,000 813,000 817,000
Credit cost ratio (credit losses / average receivables) (%) 0.8% 1.6% 1.7% 2.4% 1.6% 1.3% 3.1% 1.5% 2.9% 2.6%
Reported Mar 11, 2019 Mar 11, 2019 Mar 11, 2019 Mar 12, 2020 Mar 12, 2021 Feb 28, 2022 Mar 1, 2023 Feb 29, 2024 Feb 28, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 6, 2026 at 4:05 PM EST

PDF Version

BURLINGTON, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences.

Stifel 2026 Healthcare Conference Thursday, November 12, 2026 New York, NY Dorian LeBlanc, CFO, will present at 8:00 AM EST

Jefferies 2026 Global Healthcare Conference Tuesday, November 17, 2026 London, UK Dorian LeBlanc, CFO, will present at 10:30 AM GMT

Piper Sandler 38th Annual Healthcare Conference Thursday, December 3, 2026 New York, NY Dorian LeBlanc, CFO, will present at 8:30 AM EST

About LeMaitre LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. For more information about the Company, please visit www.lemaitre.com.

LeMaitre is a registered trademark of LeMaitre Vascular, Inc.

LeMaitre Q3 2026 Financial Results Bull 4 Bear 0 Results

November 4, 2026 at 4:05 PM EST

PDF Version

BURLINGTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q3 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance.

Q3 2026:

  • Sales $68.0mm, +11% (+12% organic) vs. Q3 2025

  • Gross margin 71.7% (-360bps, +90 bps vs. adjusted)

  • Op. expenses $31.0mm (+21%, +18% vs. adjusted)

  • Op. income $17.7mm (-13%, +5% vs. adjusted)

  • Op. margin 26%

  • EPS $0.65 (-14%, +5% vs. adjusted)

  • Cash up $13.5mm sequentially to $390mm at 9/30/2026

Grafts (+20%) and shunts (+14%) drove Q3 growth. Artegraft sales increased 18%. EMEA sales increased by 18%, Americas 9%, and APAC 5%. 12% organic growth was comprised of 7% price and 5% units.

Gross margin of 71.7% was up 90 bps (vs. adjusted) due to higher ASPs and operational efficiencies. Operating expenses increased 18% (vs. adjusted) due to Q3 2025 belt-tightening. Headcount of 678 increased 7% versus 9/30/2025 while rep count increased 13% to 171.

In October, the company acquired certain vascular assets from B. Braun for $19.2mm. These polyester and silver-coated grafts, valve cutters and vein strippers recorded sales of $9.4mm in 2025, all outside of North America. Sales will transition into LeMaitre’s channel over the next 18-24 months as B. Braun’s customer contracts conclude or transfer to LeMaitre. During this transition, LeMaitre will receive a portion of the profits on B. Braun-originated sales.

Chairman/CEO George LeMaitre said, “We expect 2026 to be another year of healthy sales (+11%) and EPS growth (+18%). Biologics continue to drive sales due to Artegraft’s international launch and the continued growth of RestoreFlow Allografts. The acquired B. Braun products will strengthen our core vascular portfolio while leveraging our expanding 31-country sales force.”

Business Outlook

| | Q4 2026 Guidance | Full Year 2026 Guidance |

| Sales | $69.9mm - $71.9mm (Mid $70.9mm, +10%, +11% org.) | $274.8mm - $276.8mm (Mid $275.8mm, +11%, +11% org.) |

| Gross Margin | 72.1% | 72.1% |

| Op. Income | $18.8mm - $20.2mm (Mid $19.5mm, +4%) | $74.6mm - $76.1mm (Mid $75.4mm, +11%, +17% adj.) |

| Op. Margin (Mid) | 27% | 27% |

| EPS | $0.70 - $0.75 (Mid $0.73, +7%) | $2.77 - $2.82 (Mid $2.80, +11%, +18% adj.) |

| | | |

  • The top- and bottom-line impacts of the newly acquired B. Braun products are reflected in this Business Outlook. LeMaitre anticipates recording ~$150,000 of Q4 2026 B. Braun product sales and break-even operating income impact. ** 2025 results include a Q3 non-recurring benefit from the Employee Retention Tax Credit. Non-GAAP adjusted figures exclude this benefit. A reconciliation of GAAP to non-GAAP measures is included.

Quarterly Dividend

On October 27, 2026, the Company's Board of Directors approved a quarterly dividend of $0.25/share of common stock. The dividend will be paid on December 3, 2026, to stockholders of record on November 19, 2026.

Share Repurchase Program

On February 19, 2026, the Company's Board of Directors authorized the repurchase of up to $100.0mm of the Company’s common stock. The repurchase program may be suspended or discontinued at any time and will conclude on February 18, 2027, unless extended by the Board.

Conference Call Reminder

Management will conduct a conference call at 5:00pm ET today. The conference call will be broadcast live over the Internet. Individuals interested in listening to the webcast can log on to the Company's website at www.lemaitre.com/investor. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. For individuals unable to join the live conference call, a replay will be available on the Company's website.

A reconciliation of GAAP to non-GAAP results is included in the tables attached to this release.

About LeMaitre

LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.

LeMaitre is a registered trademark of LeMaitre Vascular, Inc. This press release may include other trademarks and trade names of the Company.

October 12, 2026 at 4:49 PM EDT

PDF Version

BURLINGTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2026 financial results on Wednesday, November 4, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook.

Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay at ir.lemaitre.com.

About LeMaitre

LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Additional information can be found at lemaitre.com.

LeMaitre and the LeMaitre logo are registered trademarks of LeMaitre Vascular, Inc.

Prompts

LeMaitre Vascular, Inc. (ticker LMAT), listed in United States.

ETFs Holding LeMaitre Vascular, Inc.

ETF Weight in ETF Shares Market value As of
DVGR 2.54% 5,590 $ 430K Nov 18, 2026
SAWS 1.42% 1,095 $ 110.945K Jul 31, 2026
SSMG 0.78% 246 $ 24.925K Jul 31, 2026
SDVD 0.74% 85,395 $ 6.771M Nov 11, 2026
SYZ 0.42% 3,010 $ 288.84K Jun 30, 2026
SQLV 0.37% 1,096 $ 105.172K Jun 30, 2026
QIDX 0.31% 1,205 $ 122.091K Jul 31, 2026
RUSC 0.24% 1,978 $ 189.809K Jun 30, 2026
FSCC 0.16% 7,299 $ 585.964K Aug 31, 2026
FSEG 0.13% 80 $ 7,676.80 Jun 30, 2026
AFSM 0.13% 2,414 $ 185.902K Nov 16, 2026
AVSC 0.11% 46,455 $ 3.577M Nov 16, 2026
RESM 0.09% 36 $ 3,454.56 Jun 30, 2026
RILA 0.07% 273 $ 27.66K Jul 31, 2026
PSC 0.07% 16,954 $ 1.627M Jun 30, 2026
IVSS 0.05% 138 $ 13.242K Jun 30, 2026
DFAS 0.04% 170,088 $ 13.207M Nov 12, 2026
MSSM 0.01% 766 $ 61.494K Aug 31, 2026
DFAC 0.01% 91,627 $ 7.115M Nov 12, 2026
DFSU 0.01% 1,844 $ 143.187K Nov 12, 2026
DCOR 0.00% 28,194 $ 2.189M Nov 12, 2026
DFAU 0.00% 4,830 $ 375.05K Nov 12, 2026
DFUS 0.00% 6,376 $ 495.096K Nov 12, 2026
EBI 0.00% 48 $ 3,853.44 Aug 31, 2026
AVUS 0.00% 3,221 $ 248.049K Nov 16, 2026
AVSU 0.00% 48 $ 3,696.48 Nov 16, 2026